Combination treatment of AML with spleen tyrosine kinase

In this MEDtalk Philipp Sergeev, MSc, Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland, presents the results of treatment with entospletinib and lanraplenib. Lanraplenib is a next generation oral SYK inhibitor with potency and selectivity comparable to entospletinib.